Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Current Assets (2020 - 2025)

Historic Current Assets for SAB Biotherapeutics (SABS) over the last 6 years, with Q3 2025 value amounting to $113.3 million.

  • SAB Biotherapeutics' Current Assets rose 24814.71% to $113.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $113.3 million, marking a year-over-year increase of 24814.71%. This contributed to the annual value of $23.8 million for FY2024, which is 5961.04% down from last year.
  • SAB Biotherapeutics' Current Assets amounted to $113.3 million in Q3 2025, which was up 24814.71% from $9.3 million recorded in Q2 2025.
  • In the past 5 years, SAB Biotherapeutics' Current Assets ranged from a high of $113.3 million in Q3 2025 and a low of $770615.0 during Q3 2021
  • Moreover, its 5-year median value for Current Assets was $22.2 million (2022), whereas its average is $27.9 million.
  • As far as peak fluctuations go, SAB Biotherapeutics' Current Assets skyrocketed by 321815.37% in 2022, and later tumbled by 8589.98% in 2023.
  • SAB Biotherapeutics' Current Assets (Quarter) stood at $50.2 million in 2021, then tumbled by 55.97% to $22.1 million in 2022, then surged by 166.58% to $58.9 million in 2023, then tumbled by 59.61% to $23.8 million in 2024, then soared by 376.11% to $113.3 million in 2025.
  • Its last three reported values are $113.3 million in Q3 2025, $9.3 million for Q2 2025, and $16.3 million during Q1 2025.